Upload
vuongdien
View
236
Download
0
Embed Size (px)
Citation preview
c v i . s ta n fo rd .e d u | 1
March 29, 20162016 Drug Discovery
Conference Paul Berg Hall, Li Ka Shing Center
http://tinyurl.com/cvidd2016
QUARTERLY | WINTER 2016AT THE FOREFRONT OF CARDIOVASCULAR MEDICINE
February 24, 2016 Sex Differences in
Cardiovascular Health & Disease Paul Berg Hall, Li Ka Shing Center
http://tinyurl.com/wsdm2016
LEADERSHIP, SCIENCE AND FUN 2015 Highlights at the AHA The American Heart Association’s Scientific Sessions is among the leading cardiovascular conferences for basic, translational, clinical and population science. In November, Stan-ford faculty, fellows and students traveled to the Sunshine State of Florida to participate in the annual Scientific Sessions.
Leading members of the Stanford Cardiovascular Institute shared their insights on numer-ous topics. From cardiothoracic surgery, Joseph Woo, MD, led a discussion on ‘Developing a Mitral Repair Program’ and Michael Fischbein, MD, presented on developing a career in cardiovascular surgery and anesthesia. Marlene Rabinovitch, MD, Mark Nicolls, MD, and Vinicio de Jesus Perez, MD, led discussions on therapeutic avenues in pulmonary hyper-tension and targeting inflammation. Moderating the session on ‘Clinical Genomics Boot Camp’ was Euan Ashley, MD, and presenting results from the TRACER Trial were Robert Harrington, MD, and Kenneth Mahaffey, MD. A discussion on ‘Abdominal Aortic Aneu-rysms’ was led by Ronald L. Dalman, MD.
During the annual conference, CVI Director Joseph C. Wu, MD, PhD, Simon H. Stertzer Professor, received the inaugural Joseph A. Vita Award in recognition of his scientific con-tributions to the cardiovascular field.
The future of cardiovascular research and medicine lies in the fellows and students whose outstanding research will shape new treatments and understanding of health and disease. An impressive number of fellows and students presented their research at the AHA. CVI is proud to support their work and will continue to facilitate travel to conferences like the AHA through travel awards (see page 9).
Scientific Sessions 2015 abstracts are now available on the Circulation website.
Stanford at the AHA by the numbers:Abstracts 97 Presentations 42 Panelists 4 Moderators 30
The Stanford CV Med Division is currently recruiting for the following faculty positions:
• Two full-time academic advanced heart failure and transplant cardiologists in the Medical Center Line. Click for details.
• One full-time interventional cardiologist to join the VA Palo Alto in the Medical Cen-ter Line. Click for details.
• One full-time faculty member with an interest in biobank-ing and the use of biobanked samples in population research in the University Tenure Line, Medical Center Line, or Non-Tenure Line (Re-search). Click for details.
• One full-time general cardiol-ogist in the Clinician Educa-tor line. Click for details.
Upcoming Events!
c v i . s ta n fo rd .e d u | 2
Chris Austin, MD Director, NIH National Center for Advancing Translational Sciences (NCATS)
Chaitan Khosla, PhD Wells H. Rauser and Harold M. Petiprin Professor in the School of Engineering; Director, Stanford ChEM-H
Russ Altman, MD, PhD Kenneth Fong Professor and Professor, Bioengineering and Genetics Stanford University
Mark Mercola, PhD Professor Stanford University
Colleen Clancy, PhD Professor, Dept. Pharma-cology University of California, Davis
Bradley P. Morgan, PhD Vice President Drug Discovery & Early Development Cytokinetics, Inc.
Jennifer Grandis, MD Associate Vice Chancellor, Clinical and Translational Research UCSF
Sam Gambhir, MD, PhD Virginia & D.K. Ludwig Professor and Chair, Department of Radiology Stanford University
Philip Sager, MD Chair FDA Cardiorenal Drugs Advisory Committee
Norman Stockbridge, MD, PhD Director Division of Cardiovascular and Renal Products, FDA / CDER
Aarif Khakoo, MD Vice President of Research Amgen South San Francisco
Robert Harrington, MD Arthur L. Bloomfield Professor and Chair of Medicine Stanford University
Charles Homcy, MD Venture Partner, Third Rock Ventures
Joseph C. Wu, MD, PhD Simon H. Stertzer, MD, Professor & Director, Stanford Cardiovascular Institute, Stanford University
Brian Kobilka, MD Helene Irwin Fagan Chair in Cardiology and Professor, Molecular & Cellular Physiology Stanford University
Sponsored in part by
Register here: http://tinyurl.com/cvidd2016
Several advances in basic research and technology now afford us the unique opportunity to test novel diagnostic methods and therapeutics. This conference takes advantage of the collective experience and expertise of our speakers in drug discovery.
2016 Drug Discovery Conference March 29, 2016, 9:00a - 5:30p
Li Ka Shing Center for Learning & Knowledge (LKSC)
c v i . s ta n fo rd .e d u | 3
The Institute currently consists of 124 faculty members representing engineers, physicians,
surgeons, basic and clinical researchers. The mission of the Institute is integrating fundamen-
tal research across disciplines and applying technology to prevent and treat cardiovascular
disease. To support cardiovascular research and education at CVI, please contact Cathy Hut-
ton, Senior Associate Director, Medical Center Development ([email protected]) or
Dr. Joseph C. Wu, Director CVI ( [email protected]), or Ingrid Ibarra, Assistant Director of
CVI, ([email protected]).
For more information: http://cvi.stanford.edu/waystogive.html and http://cvi.stanford.edu
About the Stanford Cardiovascular Institute
Cathy Hutton Ingrid Ibarra, PhD
To understand the clinical differences and complexities of heart disease between men and women of all ages and genetic backgrounds, WSDM, CVI, and Women’s Heart Health Clinic are hosting a half-day conference.
Invited Speakers:
12:30–1:00 Lunch and poster viewing
1:00p Marcia Stefanick, PhD, Jennifer Tremmel, MD and Joseph C. Wu, MD, PhD Introduction
1:15p Patricia Nguyen, MD ‘Sex Differences in Myocardial Gene Expression’
1:40p Mintu Turakhia, MD “Gender Differences in Quality and Outcomes of Care
of Atrial Fibrillation”
2:05p Sean M. Wu, MD, PhD "Estrogen: A Friend or Foe in Viral Cardiomyopathy?"
2:30–2:45p Coffee Break
2:45p Jennifer Tremmel, MD TBD
3:10p Matthew Wheeler, MDTBD
3:35p Phillip C. Yang, MD ‘Male vs. Female Human Fetal Amniotic Mesenchymal Stem Cells: Im-
munoprivilege, Cardiac Differentiation, and Regenerative Capability’
4:00p William Fearon, MD “Sex Differences and Transcatheter Aortic Valve Replacement”
Register today! http://tinyurl.com/sexdifferences2016
Hosted by:
Sex Differences in Cardiovascular Health & Disease
February 24th 2016, 12:30 – 4:30p
Phillip Yang, MDJennifer Tremmel, MD
Patricia Nguyen, MD
Matthew Wheeler, MD
Mintu Turakhia, MD
Sean Wu, MD, PhDWilliam Fearon, MD
Marcia Stefanick, PhD
c v i . s ta n fo rd .e d u | 4
Cardiovascular Institute Annual RetreatThe 2015 annual retreat had a tremendous turnout with 61 submitted abstracts and posters and a total of 230 participants. Twelve invited speakers each represented their departments and presented work on new angles of cardiovascular health and disease. The sym-posium also featured short talks selected from fellows and students abstracts and an afternoon poster reception.
Keynotes speaker, Garret A. FitzGerald, MD (Chair, Department of Systems Pharmacology and Translational Therapeutics, University of Pennsylvania) discussed recent progress with prostanoids and inhibitors Clyde W. Yancy, MD, (Chief, Division of Medicine-Cardiology, Northwestern University) addressed racial disparities in heart failure, from the bench to the community. Entertainment was kindly pro-vided by Robert LoPresto on saxophone.
The next CVI retreat will be a joint event with the Karolinska Cardiovascular Institute on October 20, 2016. This meeting is open to the public. The goal is to incorporate other Institutes to provide new and exciting opportunities.
During the retreat five research awards were given to:Basic Research Award:
Sandra DePorter, MD, Postdoctoral Fellow, Bioengineering
Ioannis Karakikes, PhD Instructor, Cardiovascular Medicine
Alexandre Ribeiro, PhD Postdoctoral Fellow, Mechanical Engineering
Clinical Research Award:
James Priest, MD Postdoctoral Fellow in Pediatric Cardiology
Petra Mamic, MD Internal Medicine Resident
Petra Mamic, MD, Internal Medicine Resident wins clinical research prize.
c v i . s ta n fo rd .e d u | 5
At a Stanford Medicine Town Hall, three faculty members explored prospects for precision health — health care whose goal is to antici-pate and prevent disease in the healthy and precisely diagnose and treat disease in the ill.
A population-health scientist (Mark Cullen, MD), a surgeon (Mary Hawn, MD) and a geneticist (Michael Snyder, PhD) discussed how clinicians could take advantage of large health data sets and ad-vances in genomics during a panel discussion at an Oct. 12 Stan-ford Medicine Town Hall.
Moderated by Lloyd Minor, MD, Dean of the School of Medicine, the discussion focused on the future of precision health — health care whose goal is to anticipate and prevent disease in the healthy and precisely diagnose and treat disease in the ill. The town hall took place at the Li Ka Shing Center for Learning and Knowledge and was hosted by the dean; Amir Dan Rubin, president and CEO of Stanford Health Care; and Christopher Dawes, president and CEO of Stanford Children’s Health.
Faculty panel considers promises, challenges of precision health By Jennie Dusheck, Stanford Office of Communication and Public Affairs
http://med.stanford.edu/news/all-news/2015/10/faculty-panel-considers-promises-challenges-of-precision-health.html
Lloyd Minor (far left) moderates a panel discussion on precision health featuring (middle-left to right) Mark Cullen, Mary Hawn and Michael Snyder at the Li Ka Shing Center for Learning and Knowledge.
On November 6, the Vera Moulton Wall Center brought together clinicians, basic science researchers, and clinician scientists; including thought leaders from the rheumatology and pulmonary vascular disease communities for their 2nd International Symposium: Immunity and the Pathogenesis of Pulmonary Hypertension. Drs. Mark Davis of Stanford and Marc Humbert of the Universite Paris-Sud served as keynote speakers. Many left the symposium with new understanding, ideas, and collaborations that will, hopefully, impact the field in the years ahead. Thank you to the organizing committee and all who participated. Presentations will be available online in January at http://med.stanford.edu/phsymposium.html.
Vera Moulton Wall Center 2nd International Symposium
c v i . s ta n fo rd .e d u | 6
Early Sunday, November 1st more than 1,700 racers and walkers came out to participate in the Annual Race Against PH 5k on the Stanford Campus. In its 15th year, the race is put on by the Vera Moulton Wall Center for Pulmonary Vascular Disease at Stanford and brings togeth-er patients, families, practitioners, and the Stanford and general com-munity to raise awareness and funds for the fight against pulmonary hypertension (PH). Close to $50,000 was raised which will support the Wall Center Seed Grant Program. A big thank you to everyone who came out to support the event and congratulations to Stanford med-ical student, (Jonathan Tijerina) who took 1st place overall. To learn more about the Race Against PH visit raceagainstph.org.
The NIH/NHLBI Awards Stanford for PH Research
Integrative Omics as a Discovery Tool for Pulmonary Hypertension A recently awarded NIH/NHLBI project is a fruitful collaboration between the laboratories of Marlene Rabinovitch, MD, Mark R. Nicolls, MD and Michael Snyder, PhD. The project takes a systems biology approach to characterize pulmonary arterial hypertension (PAH) at the transcriptome and metabolome level of several cell types known to contribute to PAH and aims to establish a common PAH module. Sam-ples of explanted lungs from human PAH patient’s and healthy counterparts will be used to find common aberrant pathways in different vascular and inflammatory cells that could be targeted therapeutically in PAH. To study the evolution of disease, experiments in rodents will focus on the relationship of the pathways identified. In addition, new models using cultured cells derived from patients with PAH will be used to explore therapies, beginning with those that repress critical pathways.
Notable Seminars:
Dr. Rabinovitch presented at Cardiovascular Grand Rounds and Medical Grand Rounds for the 32nd Annual Laurence H. Green Lectureship, in October at Brigham and Women’s Hospital in Boston, MA. She spoke on Novel Functions of PPAR gamma in the Vascular Response to Injury.
James Tijerina (right), 1st place overall with an amazing time of 16:21.
Vera Moulton Wall Center - 15th Annual Race Against PH
Marlene Rabinovitch, MD Mark Nicolls, MD Michael Snyder, PhD
c v i . s ta n fo rd .e d u | 7
The healthy human heart is a hard-working muscle: Beating just over 100,000 beats per day, it pumps five quarts of blood per min-ute – enough to fill three supertankers worth of blood over the course of an average per-son’s lifetime.
Like any other mechanical pump, the heart is made up of various components, including
different kinds of proteins. One of those proteins, a “molecular mo-tor” called cardiac myosin (there are several varieties of myosin), plays a crucial role. A myosin molecule can oscillate lengthwise, contracting and relaxing by turns. It’s the coordinated oscillations of myriad cardiac myosin molecules that are, in the aggregate, re-sponsible for the heartbeat.
Defective cardiac myosin exacts a severe medical price. Hypertrophic cardiomyopathy, caused by mutations in a gene encoding cardiac myosin, occurs in at least one in 500 people and is a leading cause of heart failure in the United States and worldwide. It’s also the primary cause of sudden deaths due to heart attack in people under age 30.
A mutation known as R403Q, identified a couple of decades ago, ranks among the nastiest and most widely studied of literally hun-dreds of cardiac-myosin mutations. The general thinking has been that the mutation results in a “gain of function,” meaning stron-ger-than-normal myosin contractility.
Now, researchers under the direction of Stanford biochemist James Spudich, PhD, have for the first time been able to look at the effects of this mutation in human cardiac myosin as opposed to animal models. Spudich is the winner of the 2012 prestigious Lask-er Award for Basic Medical Research, is a pioneer in the analysis of myosin and its associated motility-related proteins. Integrating approaches drawn from cell physiology, physics, biochemistry, structural biology and genetics, Spudich and his colleagues have developed methods of measuring the exact amount of energy con-sumed in each contraction of a single molecule of myosin. (In my 2012 Lasker Award write-up, I explained myosin’s critical involve-ment not only in heartbeat but also in all muscular movement and, indeed, all transport of molecular materiel within every living plant or animal cell.)
In a study published in Science Advances, Spudich’s team measured the effects of the R403Q mutation at the single-molecule level and was able to demonstrate tiny, but relevant changes in the power of the mutant myosin molecule. The next step is to, in an even more sophisticated way, measure these effects in a microenvironment more closely approximating that of a living human heart.
R403Q is just the first of several hypertrophic-cardiomyopathy-in-ducing mutations the team is analyzing, one by one, with their state-of-the-art techniques.See more: http://scopeblog.stanford.edu/2015/10/12/secret-pried-from-mutinous-mutant-myosin-molecule-implicated-in-hypertrophic-cardiomyopathy/
Close-up Look at Mutinous Mutant Molecule Implicated in Hypertrophic Cardiomyopathy By Bruce Goldman
James Spudich, PhD
Researchers at Stanford have discovered, in mice, the direct progenitors to coronary artery smooth muscle cells, the important component that encases the artery and gives it strength.
The researchers, in-cluding Kristy Red-Horse, PhD, the lead author of the paper, have discovered which type of cell develops into the muscular lin-ing of arteries that feed the heart.
The finding, in mice, as well as the discovery of the molecular signals that govern this transfor-mation, may ultimately lead to human thera-pies to regrow healthy coronary arteries.
Scientists previously showed that portions of the coronary artery develop from cells on the surface of the heart called epicardial cells. However, the direct progenitors to coronary artery smooth muscle cells, the important component that encases the artery and gives it strength, were not identified.
Through a series of sophisticated tech-niques, the researchers solved the mys-tery: They determined that smooth muscle cells in cardiac arteries grew out of a kind of cell called a cardiac pericyte. Perhaps more important, scientists also identified a molecule called notch3 as the signal that governs the conversion of pericytes to cardiovascular smooth mus-cle cells.
A paper describing the work was published Oct. 19 in eLife.
“What is important about this study is that
a precise stem cell technology was used to
visualize coronary progenitors among the
millions of other cells in the developing
heart,” said Irving Weissman, MD, the Vir-
ginia and D. K. Ludwig Professor in Clinical
Investigation in Cancer Research and the
director of the Stanford Institute for Stem
Cell Biology and Regenerative Medicine,
who is a co-author of the paper. “This was
the key to discovering that pericytes turn
into smooth muscle cells in response to in-
creased blood flow.”
See more: https://med.stanford.edu/news/all-news/2015/10/precursor-cells-discovered-that-could-help-regrow-heart-arteries.html
Kristy Red-Horse, PhD
Precursor Cells Discovered that Could Help Regrow Heart Arteries By Christopher Vaughan
c v i . s ta n fo rd .e d u | 8
The National Institutes of Health halted a clinical trial on high blood pressure in order to share the results publicly right away. According to the initial study findings, managing high blood pressure so it falls below a specific blood pressure target signifi-cantly reduces rates of cardiovascular disease and lowers risk of mortality.
The Systolic Blood Pressure Intervention Trial, com-monly called SPRINT, is the largest known study of its kind to examine how holding systolic blood pres-sure below the currently recommended level affects cardiovascular and kidney diseases.
For this trial, nearly 100 medical centers in the United States and Puerto Rico, including Stanford, recruited more than 9,300 participants age 50 and older for a study that involved carefully adjusting the amount or type of blood pressure medication to achieve a target systolic pressure of 120 millimeters of mercury (mm Hg).
As outlined in an NIH press release, the researchers found that reducing systolic pressure to 120 mm Hg or less, reduced rates of stroke, heart attacks, heart failure and other cardiovascular events by almost a third and reduced the risk of death by almost a quarter, compared to the target systolic pressure of 140 mm Hg.
“SPRINT addressed a fundamental question faced by internal medicine physicians, nephrologists, cardiologists and other specialists – that is, how low should our blood pressure target be?” said Glenn Chertow, MD, MPH, principal investigator for the Stanford site.
Although researchers have known for some time that lowering patients’ blood pressure can improve survival rates and reduce their chanc-es of having a stroke, heart disease or a kidney-related event, studies that link these benefits to a specific blood pressure were lacking. This is why the SPRINT study is so important.
“Before today there was no evidence from randomized clinical trials to demonstrate that lowering systolic blood pressure toward or be-low 120 mmHg was safe and effective,” Chertow told me yesterday afternoon.
“Adoption of the approach learned from SPRINT could change medical practice and materially improve the public health,” Chertow con-tinued. “We’re proud to have participated” in the study.
http://scopeblog.stanford.edu/2015/09/11/nih-announces-initial-results-of-landmark-high-blood-pressure-study/
Vascular Surgery NewsIn October, Mattew Mell, MD, Associate Professor of Surgery (Vascular Surgery) was nominated for a new departmental role as the Department of Surgery Vice Chair for Clinical Affairs. In this position he will oversee and facilitate the quality and efficiency of clinical care for the Department of Surgery.
Nicholas Leeper, MD, assumed the role for the Division of Vascular Surgery: Chief, Vascular Med-icine and Director of Vascular Surgery Research. Dr. Leeper was also promoted to Associate Pro-fessor of Surgery as of November 1, 2015.
Matthew Mell, MD Nicholas Leeper, MD
By Holly MacCromick, Stanford University School of Medicine Social Media Producer
NIH-funded study shows effectiveness of intensive blood pressure management
c v i . s ta n fo rd .e d u | 9
Seven Stanford researchers, including Irving Weissman, MD, who directs Stanford’s Institute for Stem Cell Biology and Regenerative Medicine, and David Magnus, PhD, director of Stanford’s Center for Bio-medical Ethics, have joined with four other prominent scientists to urge the lifting of a recent and un-expected ban on funding by the National Institutes of Health for research that involves placing human stem cells into early-stage, non-human embryos. Their comments will be published tomorrow in a letter to Science.
As I describe in our release:
At issue is the growing field of research that seeks to understand how human pluripotent stem cells, which can become any cell type, may integrate and contrib-ute to the development of a nonhuman animal, such as a laboratory mouse. Pluripotent stem cells can be isolated from human embryos or created in a lab from adult human cells, in which case they’re known as induced pluripotent stem cells. Once obtained, these versatile cells can be injected into an early-stage ani-mal embryo and studied as the embryo develops into an adult animal.
Tracking where these cells go and how they function in the growing embryo and the adult animal can help re-
searchers understand early stages of human development that can’t be studied any other way. (Although researchers can and do study the development of fertilized human eggs, the study period is restricted to only a few days after fertilization for ethical reasons.)
In addition to investigating human development, the research is expected to lead to significant advanc-es in disease modeling, drug testing and even transplantation. As cardiologist and one of the co-senior authors of the letter, Sean Wu, MD, PhD, explains:
By eliminating federal funding for all aspects of this research, the NIH casts a shadow of negativity toward all experiments involving chimera studies regardless of whether human cells are involved. The current NIH restriction serves as a significant impediment to major scientific progress in the fields of stem cell and developmental biology and regenerative medicine and should be lifted as soon as possible.
Science recently published a great background article describing the ban, and its effect on researchers like Sean Wu and geneticist and stem cell researcher Hiromitsu Nakauchi, MD, PhD, who also signed the letter. Other signees include Joseph Wu, MD, PhD, professor of medicine and director of Stanford Cardiovascular Institute; Christopher Scott, PhD, director of Stanford’s Program on Stem Cells and Society; and Vittorio Sebastiano, PhD, assistant professor of obstetrics and gynecology and director of Stanford’s Human Pluripotent Stem Cells Core Facility.
See more at: http://scopeblog.stanford.edu/2015/11/05/stanford-researchers-protest-nih-funding-restrictions/
Stanford Researchers Protest NIH Funding RestrictionsBy Krista Conger, Stanford Medicine Office of Communication and Public Affairs
c v i . s ta n fo rd .e d u | 10
Since announcing the roll-out of a new Clinical Research Management System, OnCore Enterprise, in June of this year, the Stanford Center for Clinical Research (SCCR), in partnership with Spectrum, has made great strides during the pilot implementation. The Cardiovascular Institute has been a part of the pilot, with three Coordinators representing CVI’s trials. The Pilot has focused on a limited test of func-tionality and protocols. Eleven coordinators across CVI and the Department of Medicine have been trained, 5 focus groups were held with representatives from across the School of Medicine, and a new website has been created with a host of how-to guides, quick reference tips, and visual aids. Tine Bjornlund, the Research Manager for CVI, and the Divisions of Gastroenterology and Hepatology, and of Cardio-vascular Medicine within the Department of Medicine, has worked closely with Coordinators to develop workflows and gather feedback on the use of the system. Feedback has been positive, and the enthusiasm high for the long-term potential for OnCore to streamline clin-ical research operations, provide immediate reporting capabilities for leadership, and enable research staff to access standardized tools for tracking research progress.
http://med.stanford.edu/sccr.html
Streamlining Clinical Research at Stanford
Calvin Kuo, MD, PhD, professor of hematolo-gy, was elected for contributions to the fields of angiogenesis, stem cell biology and can-cer modeling, particularly for the discovery of novel molecular mediators and organoid methods. Kuo, the Maureen Lyles D’Ambroglio Professor, develops methods to grow tissues and tumor samples to create therapies for
cancer patients and discover cancer-related genes.
Hugh O’Brodovich, MD, professor and chair of pediatrics, was elected for his work in pulmonary and critical care medicine, par-ticularly for studies of the physiology and pathogenesis of respiratory distress syn-drome and bronchopulmonary dysplasia. O’Brodovich, who holds the Arline and Pete Harman Professorship for the Chair of the
Department of Pediatrics, investigates why some newborns get lung disease and others don’t.
Three members of the School of Medicine faculty have been elected members of the National Academy of Medicine, formerly known as the Institute of Medicine.
Glenn Chertow, MD, MPH; Amato Giaccia, PhD; and Robert Harrington, MD, are now among the academy’s 1,826 members and 137 international members. Dr. Harrington joined Stanford as the chair of the Department of Medicine in 2012 after serving as the director of the Duke Clinical Research Institute. He is the Arthur L. Bloomfield Professor in Medicine and a member of the Stanford Cardiovascular Institute. Harrington’s research focuses on cardiovascular disease, including mechanisms, treatments and clinical trial methodologies. He has authored or co-authored more than 400 peer-reviewed manuscripts, reviews, book chapters and editorials.
Eight faculty members from the School of Medicine and one from the School of Humanities and Sciences have been elected fellows of the American Association for the Advancement of Science. Two are members of the Stanford Cardiovascular Institute.
Recent Acknowledgements
c v i . s ta n fo rd .e d u | 11
Kitch Wilson, MD, PhD, received a K08 award en-titled ‘“Defining the Molecular Mechanism of Hy-pertrophic Cardiomyopathy with Human Induced Pluripotent Stem Cells.”
Won Hee Lee, PhD, received an AHA BGIA grant for “Identifying Biomarkers of Low-Dose Radiation Risk and Mechanisms of Individual Radiation Sensitivity.”
Elena Matsa, PhD, received an AHA BGIA as a new awardee for “Nanoparticle-mediated delivery of al-lele-specific siRNAs as a novel therapy for dilated cardiomyopathy.”
Oscar John Abilez, PhD, NIH NHLBI K01 Career De-velopment Award “Optogenetic Engineered Heart Muscle for Disease Modeling.”
Notable Fellow Awards
Travel Awards
Elias Salfati | Postdoctoral Fellow Themistocles Assimes, MD, PhD
AHA Scientific Sessions; November, 2015
‘Association between a Genetic Risk Score for Clinical CAD
and Early Stage Lesions’
Nir Qvit, PhD | Postdoctoral Fellow Daria Mochly-Rosen, PhD
American society for cell biology annual meeting, December 2015
‘Inhibition of one substrate phosphorylation of a protein kinase’
AJ Venkatakrishnan, PhD | Postdoctoral Fellow Brian Kobilka, MD
GPCR Workshop 2015
‘Rational engineering of stable G protein coupled receptors’
Tina Baykaner, MD | EP Research Fellow Sanjiv Narayan, MD
ACC Scientific Session
‘Does Atrial Fibrillation Organize Spatially or Temporally Before Termination?
Continuous Tracking of Spatio-Temporal Periodicity During Ablation’
Sang Ging Ong | Postdoctoral Fellow Joseph C. Wu, MD PhD
AHA Scientific Sessions; November, 2015
‘Exosomal microRNA Transfer in Ischemic Heart Disease’
Rushi Parikh, MD | CV Med Fellow William F. Fearon, MD
ACC Scientific Sessions
‘Higher Levels of Asymmetric Dimethylarginine are Associated with Lower
Fractional Flow Reserve After Orthotopic Heart Transplantation’
c v i . s ta n fo rd .e d u | 12
MONTHLY CVIFACULTY CLUB
Discuss your latest research or just unwind
with your peers with wine & cheese
Monthly, 4:30 p.m.
in Lorry Lokey G1161
Beth Pruitt, PhDNSF |‘EFRI-MIKS: Force Sensing and
Remodeling by Cell-Cell Junctions
in Multicellular Tissues
Russ B. Altman, MD, PhD NIH | PharmGKB: From
Association to Mechanism
Marcia L. Stefanick, PhD NIH | Women’s Health
Initiative - Regional Centers 2015-2020
Seda Tierney, MDAHA | On-line Intervention to Lower
Cardiovascular Risk in Pediatric Heart Transplant Patients
Kristy Red-Horse, PhDNew York Stem Cell Foundation |
Regenerating coronary arteries by stimu-lating progenitor cell differentiation
Sean Mackey, MDNIH | Single Session Pain
Catastrophizing Treatment: Comparative Efficacy &
Mechanisms
Recently Awarded Projects
William F. Fearon, MD Assessment of Catheter-based Interrogation and Standard Techniques for Fractional Flow Reserve measurement: the ACIST-FFR study
Robert Harrington, MDClinical Trial Services - A Phase 2b, Multi-center, Ran-domized, Placebo-controlled, Dose-ranging Study to Investigate the Safety and Tolerability of Multiple Dose Administration of CSL112 in Subjects with Acute Myocardial Infarction
Jason T. Lee, MD• Endurant EVO US Clinical Trial (Medtronic Vascular, Inc.)
• TriVascular Evaluation of FemaLes who are Underrepresented Candidates for Abdominal Aortic AneurYsm Repair (Trivascular, Inc.)
Nicholas J. Leeper, MDAn international, multicenter, randomized, dou-ble-blind, placebo-controlled phase 3 trial investigat-ing the efficacy and safety of rivaroxaban to reduce the risk of major thrombotic vascular events in patients with symptomatic peripheral artery disease
undergoing lower extremity revascularization procedures(Bayer Healthcare Pharmaceuticals, Inc.)
New Clinical Trials
New CVI Staff
Clinical Research Coordinator Maja Cruz, Joins CVIMaja Cruz has joined the Stanford clinical trial coordinating group. She was previously with the Stanford Blood and Marrow Transplant and Stanford Sleep Medicine before joining the Cardiovascular Institute. She completed an MD at the University of Santo Tomas Faculty of Medicine and Surgery in the Philippines. Currently she is working on Ischemia trials and industry- sponsored Cardiology and Vascular trials.
Details: http://med.stanford.edu/cvi/translational-research/clinical-trials.html
c v i . s ta n fo rd .e d u | 13
FEBRUARY
Wallace H. Coulter Translation Research Grant Program Stanford Coulter – Translational Research Grants Deadline: Feb. 1, 2016 Coulter
Progeria Research Foundation Research Grants (Innovative, Established Investigator, Specialty awards) Deadline: Feb. 2, 2016 Progeria Research
National Institute of Health Improving Outcomes in Cancer Treatment-Related Cardiotoxicty (R01) Deadline: Feb. 12, 2016 R01: PA-16-035
Improving Outcomes in Cancer Treatment-Related Cardiotoxicty (R21) Deadline: Feb. 16, 2016 R21: PA-16-036
NHLBI Clinical Trial Pilot Studies Deadline: Feb. 16, 2016 PAR-16-037
NHLBI Progenitor Cell Translational Consortium Deadline: Feb. 8, 2016 RFA-HL-16-021
Faculty Funding Opportunities
Postdoctoral Funding OpportunitiesFEBRUARY
Stanford Child Health Research Institute (CHRI) Clinical Trainee Support Deadline: Feb. 1, 2016 CHRI Clinical Trainee
National Institute of Health K99/R00 NIH Pathway to Independence Award Deadline: Feb. 12, 2016 PA-15-083
K08 Mentored Clinical Research Career Development Award Deadline: Feb. 12, 2016 PA-14-046
K23 Mentored Patient-Oriented Research Career Development Award Deadline: Feb. 12, 2016 PA-14-049
NHLBI K01 Mentored Career Development Award to Promote Faculty Diversity Deadline: Feb. 12, 2016 RFA-HL-16-006
Marfan Foundation Victor A. McKusick Fellowship Program Deadline: Feb. 16, 2016 Marfan Foundation
Early Investigator Grant Program Deadline: Feb. 16, 2016 Marfan Foundation
MARCH
Spectrum Education Program TL1 Clinical Research Training Program Deadline: March 1, 2016 Spectrum
Stanford University – CVI Fellowship Training Program (T32) Multi-Disciplinary Training Program in Cardiovascular Imaging Deadline: March 1, 2016 CVI Fellowship
Thrasher Research Fund Early Career Awards Deadline: March 15, 2016 Thrasher Early Career Awards
Stanford University – CVI Fellowship Training Program (T32) Mechanisms & Innovation in Vascular Disease Deadline: March 15, 2016 CVI Fellowship
APRIL
National Institute of Health Ruth L. Kirschstein National Research Service Awards (NRSA) for Individual Postdoctoral Fellows Deadline: April 8, 2016 PA-14-149
Marfan Foundation Victor A. McKusick Fellowship Program Deadline: April 11, 2016 Marfan Foundation
2016 CVI Faculty Club This informal meet-up is tai-lored to Stanford faculty and Instructors only. Once a month (first Wednesday of the month) one or two CVI faculty members will present their research aims to their colleagues to receive feedback and input. Please contact Crystal Both-am, PhD ([email protected]) with questions and request to present at CVI Faculty Club. Join us! Lorry Lokey Stem Cell Building, G1161 at 4:30p
January 6 MARY TERUEL, PHD A circadian code for fat cell differentiation
February 3 DOMINIK FLEISCHMANN, MD Aortic Dissection: Morphology and
Function
March 2 MICHAEL CORONADO TBD
April 6 PHILIP S. TSAO, PHD MicroRNA
Regulation of Blood Brain Barrier
Function and Hypoperfusion-induced
Cerebrovascular Disease
May 4 JARED CHURKO, PHD Transcriptomic
analysis of hiPSCs to cardiomyocytes
June 1 Y. JOSEPH WOO, MD and AMANDA STEELE A Pilot study for an engineered HGF
fragment for the treatment of myocardial
infarction in a preclincal ovine model
September 7 KENNETH MAHAFFEY, MD, RYAN O’MALLEY; FANCOIS HADDAD, HOLDEN MAECKER, MARK DAVIS Defining
the role of Immune Biomarkers in Non-ST
Elevation Myocardial Infarction: analysis
from TRACER trial biorepository
October 5 EVGENIOS NEOFYTOU, MD Modeling Chronic Chagasic Cardiomyopathy
Disease Mechanisms Using Human induced
Pluripotent Stem Cells
November 2 MICHAEL MCCONNELL, MD TBD
December 7 ANITRA ROMFH, MD and MANISH BUTTE, MD, PHD T-Cell Deficiencies
in Adult Congenital Heart Disease
c v i . s ta n fo rd .e d u | 14
2016Frontiers in Cardiovascular Science
Li Ka Shing Center for Learning & Knowledge | 291 Campus Drive, Stanford, CA 94305Tuesdays from 12:00 - 1:00pm (unless otherwise stated)
cvi.stanford.edu
JANUARY 12, 2016Stanley Hazen, MD, PhDDirector, Center for Cardiovascular Diagnostics & Prevention; Section Head, Preventive Cardiology & Rehabilitation
JANUARY 19, 2016 Jonathan Seidman, PhDProfessor, Department of Genetics Harvard Medical School
JANUARY 26, 2016 Dominik Fleischmann, MDProfessor of Radiology, Stanford School of Medicine &Patricia Nguyen, MDAssistant Professor of Medicine Palo Alto Veterans Affairs Health Care System
FEBRUARY 9, 2016 Aruni Bhatnagar, PhDProfessor of Medicine, University of Louisville12:30 - 1:30 p.m.
FEBRUARY 16, 2016Eric J. Topol, MDDirector, Scripps Translational Science Institute
FEBRUARY 23, 2016Helen M. Blau, PhDThe Donald E. and Delia B. Baxter Foundation Professor Stanford School of Medicine
MARCH 01, 2016 Todd Rosengart, MD, FACSProfessor of Surgery and DeBakey-Bard Chair of Surgery; Texas Heart Institute
MARCH 08, 2016Jonathan S. Stamler, MDDirector, Harrington Discovery Institute, Case Western Reserve University School of Medicine
MARCH 15 2016Linda L. Demer, MD, PhDM.C. Guthman Professor of Medicine and Physiology; Director, UCLA STAR Program, UCLA
MARCH 22 2016Andrew Plump, MD, PhDChief Medical and Scientific Officer Takeda Pharmaceutical Company
APRIL 05, 2016Mark Nicolls, MDAssociate Professor of Medicine (Pulmonary and Critical Care), Stanford School of Medicine
APRIL 12, 2016Calum A. MacRae, MD, PhDChief, Cardiovascular Medicine, Harvard Medical School; Brigham and Women’s Hospital
April 19Mark Hlatky, MDProfessor of Health Research and Policy, Stanford University
MAY 10, 2016Phil Tsao, PhD Professor of Medicine (Cardiovascular Medicine)Stanford School of Medicine &Themistocles Assimes, PhDAssistant Professor of Medicine (Cardiovascular Medicine), Stanford School of Medicine
MAY 24, 2016Edward Yeh, MDProfessor and Chair Dept. of Cardiology MD Anderson Cancer Center
MAY 31, 2016Thomas F. Lüscher, MD, FRCPProfessor and Chairman of Cardiology, U. Hospital Zurich; University Zurich
c v i . s ta n fo rd .e d u | 15
Cardiovascular Global Conferences
MED223: Cardiovascular & Pulmonary Research
FEBRUARY
Vascular and Endovascular Surgery Society – Annual Winter Meeting February 4-7, 2016 Park City, Utah http://www.pvss.org/
International Stroke Conference February 16-19, 2016 Los Angeles, California Stroke Conference
Stanford Sex Differences in Cardiovas-cular Health & Disease February 24, 2016 Stanford, California Sex Differences
Quality of Care and Outcomes Research 2015 February 28 – March 1, 2016 Phoenix, Arizona QCOR 2016
MARCH
Epidemiology and Prevention; Lifestyle and Cardiometabolic Health March 1-4, 2016 Phoenix, Arizona EPI LIFESTYLE 2015
International Congress of Update in Cardiology and Cardiovascular Surgery March 10-13, 2016 Antalya, Turkey UCCVS 2016
Society for Clinical Vascular Surgery Annual Symposium March 12-16, 2016 Las Vegas, Nevada http://scvs.org
Stanford 2016 Drug Discovery Conference March 29, 2016 Stanford, California Drug Discovery
APRIL
American College of Cardiology Scientific Session & Expo April 2-4, 2016 Chicago, Illinois http://accscientificsession.cardiosource.
org/ACC.aspx
Heart Failure: Genetics, Genomics and Epigenetics April 3 – 7, 2016 Snowbird, Utah Keystone Symposia
Cardiac Development, Regeneration and Repair April 3 – 7, 2016 Snowbird, Utah Keystone Symposia
New Therapeutics for Diabetes and Obesity April 17 - 20, 2016 La Jolla, California Keystone Symposia
The focus of MED223 is to fine tune critical thinking skills by analyzing original publications and un-der-stand the current complexities of the cardiovascular and pulmonary system. Students will attend a lecture series presented by prominent external speakers on Tuesdays (12:00–1:00p at LKSC—Followed by lunch or coffee with external speaker) and learn new approaches and medical advances from Stanford faculty on Thursdays (12:30–1:20p at SIM1 G1002). Winter 2016, 3 Credits
Christopher Almond, MD Assistant Professor of Pediatrics (Cardiology), Lucile Packard Children’s Hospital
Marcia L. Stefanick, PhD Professor (Research) of Medicine Stanford Prevention Research Center) and of Obstetrics & Gynecology
James Spudich, PhD Douglass M. and Nola Leishman Professor of Cardiovascular Disease
Thomas Quertermous, MD Professor, Chief Divison of Cardiovascular Medicine
Cornelia Weyand, MD Professor, Chief Divison of Immunology and Rheumatology
Stanley G. Rockson, MD Professor of Lymphatic Research and Medicine
Joshua W. Knowles, MD Assistant Professor of Medicine (Cardiovascular Medicine)
Edda Spiekerkoetter, MD Assistant Professor of Medicine (Pulmonary and Critical Care Medicine)
Winter 2016- Internal Speakers
c v i . s ta n fo rd .e d u | 16
Our MissionWe provide quantitative assessment of clinical cardiovascular phenotypes for translational research and clinical tri-als. These cardiovascular phenotypes include evaluating cardiac structure and function, measuring carotid intimal thickness and arterial stiffness, and test-ing endothelial function and cardiopul-monary exercise testing.
In collaboration with the Human Im-mune Monitoring Center at Stanford and members of the Cardiovascular Institute, we also offer central blood processing and banking capabilities. In addition, we develop new biomarker platforms and imaging modalities.
Key Initiatives1. Stanford Athletic Screening Program. The BPCL is the core laboratory responsible for the echocar-diographic studies of Stanford Athletic Screening Program and has imaged more than 500 athletes.
2. Stanford Immune Aging Longitudinal Study. The BPCL is the core providing clinical cardiovascular phenotypes for collaboration through the NIH funded projects of the Immunity Transplantation and Infection Institute led by Mark Davis, MD.
3. The Pulmonary Hypertension Wall Center Outcome and Physiology Studies. The BPCL works closely with the Vera Moulton Wall Center for Pulmonary Vascular Disease to provide quantitative echocardiographic assessment of the right heart.
4. The CCML-Stanford Collaborative Effort. Through a close collaboration with the University of Paris and the Marie-Lannelongue surgical center (CCML), the BPCL is providing quantitative analysis of experimental and clinical studies focused on right heart physiology. The CCML is a recognized worldwide center of expertise in pulmonary hypertension (Elie Fadel MD PhD and Olaf Mercier MD PhD).
Clinical Biomarker & Phenotyping Core Lab (BPCL)
Biobank
Stanford CVI Human iPSC Biobank ServiceNormal and patient-derived reprogrammed cardiomyocytes is a tremendous resource for re-searchers and physicians here at Stanford and around the country. Understanding the disease process directly at the population level and observing these cells as surrogates under a myr-iad conditions has the potential to be a game-changer for cardiovascular medical research.
To facilitate research in a dish that allows screening of new compounds or characterization of human disease phenotypes using cardiomyocytes, the Institute created a service by which de-identified PBMC samples from selected patients can be sent to Stanford CVI for repro-gramming free of cost. Please contact Joseph Wu, MD, PhD ( [email protected]) or Bio-bank manager, Justin Vincent ( [email protected]), with any questions.
SCVI biobank is supported in part by National Heart, Lung and Blood Institute (NHLBI), the California Institute for Regenerative Medicine (CIRM), and the Stanford Cardiovascular Insti-tute (CVI). Stanford iPSC Biobank was recently mentioned in Nature Methods news: http://www.nature.com/nmeth/journal/v12/n2/full/nmeth.3263.html.
Lab Resources
Contact UsFrancois Haddad, MD ([email protected]) or Ingrid Ibarra, PhD ([email protected]) at CVI.
3DQ Imaging LaboratoryStanford’s 3DQ Imaging Laboratory was established in 1996 at Stanford by Geof-frey Rubin, MD, and Sandy Napel, PhD, Professor of Radiology (General Radiol-ogy) and, by courtesy, Electrical Engi-neering. Today the center is co-directed by Dominik Fleischmann, MD, Profes-sor of Radiology (General Radiology) and Roland Bammer, PhD, Associate Professor (Research) of Radiology.
Currently the lab processes over 1,200 clinical cases per month. Linda Horst, Marc Sofilos, and Shannon Walters are an integral part of the 3DQ Lab manage-ment team.
For more visit: http://3dqlab.stanford.
edu/
c v i . s ta n fo rd .e d u | 17
Communication is at the heart of scientific advancement and innovation. This quarter the Stanford Cardiovascular Institute members published over 240 original manuscripts and reviews further contributing to our understanding of cardiovascular biology and disease. In the following pages, we highlight selected manuscripts by our members.
Member Publications
OCTOBER 2015: 149 PUBLICATIONS
A Pilot Study Assessing ECG vs. ECHO Ventriculo-Ventricular Optimization in Pe-
diatric Resynchronization Patients. Punn R, Hanisch D, Motonaga KS, Rosen-thal DN, Ceresnak SR, Dubin AM. J Cardiovasc Electrophysiol. 2015 Oct 30.
A Crack in the Wall: Evolution of a Left Ventricular Apical Pseudoaneurysm.
Parikh RV, Ahmadi-Kashani M, Fleischmann D, Woo YJ, McConnell MV. Can
J Cardiol. 2015 Jul 17.
Diabetic Cardiovascular Disease Induced by Oxidative Stress. Kayama Y,
Raaz U, Jagger A, Adam M, Schellinger IN, Sakamoto M, Suzuki H, Toyama
K, Spin JM, Tsao PS. Int J Mol Sci. 2015 Oct 23;16(10):25234-63.
Optimized measurements of separations and angles between intra-molec-
ular fluorescent markers. Mortensen KI, Sung J, Flyvbjerg H, Spudich JA.
Nat Commun. 2015 Oct 16;6:8621.
Debate: Whether branched/fenestrated endovascular aneurysm repair pro-
cedures are better than snorkels, chimneys, or periscopes in the treatment
of most thoracoabdominal and juxtarenal aneurysms. Hertault A, Haulon
S, Lee JT. J Vasc Surg. 2015 Nov;62(5):1357-65.
Integrated Physiologic Assessment of Ischemic Heart Disease in Real-World
Practice Using Index of Microcirculatory Resistance and Fractional Flow
Reserve: Insights From the International Index of Microcirculatory Resis-
tance Registry. Lee JM, Layland J, Jung JH, Lee HJ, Echavarria-Pinto M,
Watkins S, Yong AS, Doh JH, Nam CW, Shin ES, Koo BK, Ng MK, Escaned J,
Fearon WF, Oldroyd KG. Circ Cardiovasc Interv. 2015 Nov;8(11).
Establishing disease causality for a novel gene variant in familial dilat-
ed cardiomyopathy using a functional in-vitro assay of regulated thin
filaments and human cardiac myosin. Pan S, Sommese RF, Sallam KI, Nag
S, Sutton S, Miller SM, Spudich JA, Ruppel KM, Ashley EA. BMC Med Genet.
2015 Oct 26;16(1):97.
Qualitative grading of aortic regurgitation: a pilot study comparing CMR 4D
flow and echocardiography. Chelu RG, van den Bosch AE, van Kranenburg
M, Hsiao A, van den Hoven AT, Ouhlous M, Budde RP, Beniest KM, Swart LE,
Coenen A, Lubbers MM, Wielopolski PA, Vasanawala SS, Roos-Hesselink
JW, Nieman K. Int J Cardiovasc Imaging. 2015 Oct 24. [Epub ahead of print]
A cellular, molecular, and pharmacological basis for appendage regenera-
tion in mice. Leung TH, Snyder ER, Liu Y, Wang J, Kim SK. Genes Dev. 2015
Oct 15;29(20):2097-107.
Surveillance of Stem Cell Fate and Function: A System for Assessing Cell
Survival and Collagen Expression In Situ. Walmsley GG, Senarath-Yapa
K, Wearda TL, Menon S, Hu MS, Tsai JM, Zielins ER, Duscher D, Maan ZN,
Weissman IL, Gurtner GC, Lorenz HP, Longaker MT. Tissue Eng Part A.
2015 Oct 21.
Redox regulation of vascular remodeling. Karimi Galougahi K, Ashley EA,
Ali ZA. Cell Mol Life Sci. 2015 Oct 20.
Team-Based Care and Quality: A Move Toward Evidence-Based Policy. Har-rington RA, Heidenreich PA. J Am Coll Cardiol. 2015 Oct 20;66(16):1813-5.
Rationale and Design of Sodium Tanshinone IIA Sulfonate in Left Ventricu-
lar Remodeling Secondary to Acute Myocardial Infarction (STAMP-REMOD-
ELING) Trial: A Randomized Controlled Study. Mao S, Li X, Wang L, Yang PC, Zhang M. Cardiovasc Drugs Ther. 2015 Oct 20.
Cardioplegia Dose Effect on Immediate Postoperative Alterations in Coro-
nary Artery Flow Velocities After Congenital Cardiac Surgery. Davidson H,
Punn R, Tacy TA. Pediatr Cardiol. 2015 Oct 20. [Epub ahead of print]
Pericytes are progenitors for coronary artery smooth muscle. Volz KS,
Jacobs AH, Chen HI, Poduri A, McKay AS, Riordan DP, Kofler N, Kitajewski J,
Weissman I, Red-Horse K. Elife. 2015 Oct 19;4.
Phase Synchrony Reveals Organization in Human Atrial Fibrillation.
Vidmar D, Narayan SM, Rappel WJ. Am J Physiol Heart Circ Physiol. 2015 Oct
16:ajpheart.00407.2015.
Quality-of-Life and Economic Outcomes of Assessing Fractional Flow
Reserve With Computed Tomography Angiography: PLATFORM. Hlatky MA,
De Bruyne B, Pontone G, Patel MR, Norgaard BL, Byrne RA, Curzen N, Pur-
cell I, Gutberlet M, Rioufol G, Hink U, Schuchlenz HW, Feuchtner G, Gilard
M, Andreini D, Jensen JM, Hadamitzky M, Wilk A, Wang F, Rogers C, Douglas
PS; PLATFORM Investigators. J Am Coll Cardiol. 2015 Dec 1;66(21):2315-23.
Increased red cell distribution width is associated with poor stem cell
mobilization in patients with advanced chronic heart failure. Poglajen G,
Sever M, Černelč P, Haddad F, Vrtovec B. Biomarkers. 2015 Sep;20(6-7):365-
70.
Immunologic and Infectious Diseases in Pediatric Cardiac Critical Care:
Proceedings of the 10th International Pediatric Cardiac Intensive Care
Society Conference. Axelrod DM, Alten JA, Berger JT, Hall MW, Thiagarajan
R, Bronicki RA. World J Pediatr Congenit Heart Surg. 2015 Oct;6(4):575-87.
Monitoring Pharmacologically Induced Immunosuppression by Immune
Repertoire Sequencing to Detect Acute Allograft Rejection in Heart Trans-
plant Patients: A Proof-of-Concept Diagnostic Accuracy Study. Vollmers
C, De Vlaminck I, Valantine HA, Penland L, Luikart H, Strehl C, Cohen G,
Khush KK, Quake SR. PLoS Med. 2015 Oct 14;12(10):e1001890.
Sleep disruption impairs haematopoietic stem cell transplantation in
mice. Rolls A, Pang WW, Ibarra I, Colas D, Bonnavion P, Korin B, Heller HC,
Weissman IL, de Lecea L. Nat Commun. 2015 Oct 14;6:8516.
Local Stent-Based Release of Transforming Growth Factor-β1 Limits Arteri-
al In-Stent Restenosis. Wang DS, Ganaha F, Kao EY, Lee J, Elkins CJ, Waugh
JM, Dake MD. J Lab Autom. 2015 Oct 13.
c v i . s ta n fo rd .e d u | 18
Fluorescence Imaging In Vivo at Wavelengths beyond 1500 nm. Diao S,
Blackburn JL, Hong G, Antaris AL, Chang J, Wu JZ, Zhang B, Cheng K, Kuo CJ, Dai H. Angew Chem Int Ed Engl. 2015 Oct 13.
Noninvasive monitoring of infection and rejection after lung transplan-
tation. De Vlaminck I, Martin L, Kertesz M, Patel K, Kowarsky M, Strehl C,
Cohen G, Luikart H, Neff NF, Okamoto J, Nicolls MR, Cornfield D, Weill D, Valantine H, Khush KK, Quake SR. Proc Natl Acad Sci U S A. 2015 Oct
27;112(43):13336-41.
Mifepristone Treatment of Cushing’s Syndrome in a Pediatric Patient.
Banerjee RR, Marina N, Katznelson L, Feldman BJ. Pediatrics. 2015
Nov;136(5):e1377-81.
Maternal Midpregnancy Glucose Levels and Risk of Congenital Heart
Disease in Offspring. Priest JR, Yang W, Reaven G, Knowles JW, Shaw GM.
JAMA Pediatr. 2015 Oct 12:1-5.
Gender Differences in Ventricular Remodeling and Function in College
Athletes, Insights from Lean Body Mass Scaling and Deformation Imaging.
Giraldeau G, Kobayashi Y, Finocchiaro G, Wheeler M, Perez M, Kuznetsova
T, Lord R, George KP, Oxborough D, Schnittger I, Froelicher V, Liang D,
Ashley E, Haddad F. Am J Cardiol. 2015 Nov 15;116(10):1610-6.
The basic helix-loop-helix transcription factor, Mist1, induces maturation
of mouse fetal hepatoblasts. Chikada H, Ito K, Yanagida A, Nakauchi H,
Kamiya A. Sci Rep. 2015 Oct 12;5:14989.
Reference Standards for Cardiorespiratory Fitness Measured With Car-
diopulmonary Exercise Testing: Data From the Fitness Registry and the
Importance of Exercise National Database. Kaminsky LA, Arena R, Myers J.
Mayo Clin Proc. 2015 Nov;90(11):1515-23.
Characteristics, Treatments, and Outcomes of Hospitalized Heart Failure
Patients Stratified by Etiologies of Cardiomyopathy. Shore S, Grau-Sepul-
veda MV, Bhatt DL, Heidenreich PA, Eapen ZJ, Hernandez AF, Yancy CW,
Fonarow GC. JACC Heart Fail. 2015 Nov;3(11):906-16.
Clinician Innovator: A Novel Career Path in Academic Medicine A Pres-
identially Commissioned Article From the American Heart Association.
Majmudar MD, Harrington RA, Brown NJ, Graham G, McConnell MV. J Am
Heart Assoc. 2015 Oct 8;4(10).
Sequence to Medical Phenotypes: A Framework for Interpretation of
Human Whole Genome DNA Sequence Data. Dewey FE, Grove ME, Priest JR, Waggott D, Batra P, Miller CL, Wheeler M, Zia A, Pan C, Karzcewski
KJ, Miyake C, Whirl-Carrillo M, Klein TE, Datta S, Altman RB, Snyder M,
Quertermous T, Ashley EA. PLoS Genet. 2015 Oct 8;11(10):e1005496.
The Cutaneous, Net Clinical, and Health Economic Benefits of Advanced Pneu-
matic Compression Devices in Patients With Lymphedema. Karaca-Mandic P,
Hirsch AT, Rockson SG, Ridner SH. JAMA Dermatol. 2015 Nov 1;151(11):1187-93.
Bilayered vascular graft derived from human induced pluripotent stem
cells with biomimetic structure and function. Nakayama KH, Joshi
PA, Lai ES, Gujar P, Joubert LM, Chen B, Huang NF. Regen Med. 2015
Sep;10(6):745-55.
Chemically Defined Culture and Cardiomyocyte Differentiation of Human
Pluripotent Stem Cells. Burridge PW, Holmström A, Wu JC. Curr Protoc Hum
Genet. 2015 Oct 6;87:21.3.1-21.3.15.
Letter by Wheeler et al Regarding Article, “Recognition and Significance
of Pathological T-Wave Inversions in Athletes”. Wheeler MT, Adelfattah R,
Froelicher VF. Circulation. 2015 Oct 6;132(14):e180.
β-Blocker-Associated Risks in Patients With Uncomplicated Hypertension
Undergoing Noncardiac Surgery. Jørgensen ME, Hlatky MA, Køber L, Sand-
ers RD, Torp-Pedersen C, Gislason GH, Jensen PF, Andersson C. JAMA Intern
Med. 2015 Oct 5:1-9.
Formation of a Neurosensory Organ by Epithelial Cell Slithering. Kuo CS,
Krasnow MA. Cell. 2015 Oct 8;163(2):394-405.
Prospective Analysis of Health and Mortality Risk in Veteran and Non-Vet-
eran Participants in the Women’s Health Initiative. Weitlauf JC, LaCroix
AZ, Bird CE, Woods NF, Washington DL, Katon JG, LaMonte MJ, Goldstein MK, Bassuk SS, Sarto GE, Stefanick ML. Womens Health Issues. 2015 Nov-
Dec;25(6):649-57.
Midterm Outcomes of Open Descending Thoracic Aortic Repair in More
Than 5,000 Medicare Patients. Schaffer JM, Lingala B, Fischbein MP, Dake MD, Woo YJ, Mitchell RS, Miller DC. Ann Thorac Surg. 2015 Sep 29
Regional right ventricular dysfunction in acute pulmonary embolism:
relationship with clot burden and biomarker profile. Tuzovic M, Adigopula
S, Amsallem M, Kobayashi Y, Kadoch M, Boulate D, Krishnan G, Liang D,
Schnittger I, Fleischmann D, McConnell MV, Haddad F. Int J Cardiovasc
Imaging. 2015 Oct 1.
Engineered heart tissues and induced pluripotent stem cells: Macro- and
microstructures for disease modeling, drug screening, and translational
studies. Tzatzalos E, Abilez OJ, Shukla P, Wu JC. Adv Drug Deliv Rev. 2015
Sep 30.
The ORBIT bleeding score: a simple bedside score to assess bleeding risk
in atrial fibrillation. O’Brien EC, Simon DN, Thomas LE, Hylek EM, Gersh
BJ, Ansell JE, Kowey PR, Mahaffey KW, Chang P, Fonarow GC, Pencina MJ,
Piccini JP, Peterson ED. Eur Heart J. 2015 Sep 29. [Epub ahead of print]
Multimodality Imaging of Cancer Superoxide Anion Using the Small Mol-
ecule Coelenterazine. Bronsart LL, Stokes C, Contag CH. Mol Imaging Biol.
2015 Sep 29.
Genetic risk for atrial fibrillation could motivate patient adherence to
warfarin therapy: a cost effectiveness analysis. Shiffman D, Perez MV,
Bare LA, Louie JZ, Arellano AR, Devlin JJ. BMC Cardiovasc Disord. 2015 Sep
29;15(1):104.
c v i . s ta n fo rd .e d u | 19
NOVEMBER 2015: PUBLICATIONS
Longitudinal Cognitive Trajectories of Women Veterans from the Wom-
en’s Health Initiative Memory Study. Padula CB, Weitlauf JC, Rosen AC,
Reiber G, Cochrane BB, Naughton MJ, Li W, Rissling M, Yaffe K, Hunt JR,
Stefanick ML, Goldstein MK, Espeland MA. Gerontologist. 2015 Nov 27.
The Precise Timing of Tachycardia Entrainment is Determined by the
Post-Pacing Interval, the Tachycardia Cycle Length, and the Pacing Rate:
Theoretical Insights and Practical Applications. Kaiser DW, Hsia HH,
Dubin AM, Liem LB, Viswanathan MN, Zei PC, Wang PJ, Narayan SM,
Turakhia MP. Heart Rhythm. 2015 Nov 20.
Gastrointestinal Bleeding in Patients With Atrial Fibrillation Treated With
Rivaroxaban or Warfarin: ROCKET AF Trial. Sherwood MW, Nessel CC,
Hellkamp AS, Mahaffey KW, Piccini JP, Suh EY, Becker RC, Singer DE,
Halperin JL, Hankey GJ, Berkowitz SD, Fox KA, Patel MR. J Am Coll Cardiol.
2015 Dec 1;66(21):2271-81.
Mechanistically-based mapping of human cardiac fibrillation. Narayan SM, Zaman JA. J Physiol. 2015 Nov 26.
Discovering the truth about life after discharge: Long-term trauma related mor-
tality. Callcut RA, Wakam G, Conroy AS, Kornblith LZ, Howard BM, Campion EM,
Nelson MF, Mell MW, Cohen MJ. J Trauma Acute Care Surg. 2015 Nov 24.
Part Two: Against the Motion. Fenestrated EVAR Procedures are not
Better than Snorkels, Chimneys, or Periscopes in the Treatment of Most
Thoracoabdominal and Juxtarenal Aneurysms. Lee JT. Eur J Vasc Endo-
vasc Surg. 2015 Nov;50(5):557-61.
Mitral Stenosis and Aortic Atresia-A Risk Factor for Mortality After the
Modified Norwood Operation in Hypoplastic Left Heart Syndrome. Siehr
SL, Maeda K, Connolly AA, Tacy TA, Reddy VM, Hanley FL, Perry SB,
Wright GE. Ann Thorac Surg. 2015 Nov 18. pii: S0003-4975(15)01564-7.
Contractility parameters of human β-cardiac myosin with the hypertro-
phic cardiomyopathy mutation R403Q show loss of motor function. Nag
S, Sommese RF, Ujfalusi Z, Combs A, Langer S, Sutton S, Leinwand LA,
Geeves MA, Ruppel KM, Spudich JA. Sci Adv. 2015 Oct 9;1(9):e1500511.
Predictors and outcomes of endoleaks in the Veterans Affairs Open
Versus Endovascular Repair (OVER) Trial of Abdominal Aortic Aneurysms.
Lal BK, Zhou W, Li Z, Kyriakides T, Matsumura J, Lederle FA, Freischlag
J; OVER Veterans Affairs Cooperative Study Group. J Vasc Surg. 2015
Dec;62(6):1394-404.
Dietary fructose in pregnancy induces hyperglycemia, hypertension, and
pathologic kidney and liver changes in a rodent model. Shortliffe LM,
Hammam O, Han X, Kouba E, Tsao PS, Wang B. Pregnancy Hypertens. 2015
Oct;5(4):308-14.
CDKN2B Regulates TGFβ Signaling and Smooth Muscle Cell Investment
of Hypoxic Neovessels. Nanda V, Downing KP, Ye J, Xiao S, Kojima Y, Spin JM, DiRenzo DM, Nead K, Connolly AJ, Dandona S, Perisic L, Hedin U,
Maegdefessel L, Dalman J, Guo L, Zhao X, Kolodgie FD, Virmani R, Davis
HR, Leeper N. Circ Res. 2015 Nov 23.
Percutaneous Cryoablation for Successful Treatment of a Persistent
Urine Leak after Robotic-Assisted Partial Nephrectomy. Ward TJ, Ahmed
O, Chung BI, Sze DY, Hwang GL. J Vasc Interv Radiol. 2015 Dec;26(12):1867-
70.
Should We Start Community Screening for Left Ventricular Dysfunction?
Heidenreich PA. J Card Fail. 2015 Nov 16.
Multiplexed Fluid Flow Device to Study Cellular Response to Tunable
Shear Stress Gradients. Ostrowski MA, Huang EY, Surya VN, Poplawski C,
Barakat JM, Lin GL, Fuller GG, Dunn AR. Ann Biomed Eng. 2015 Nov 20.
Frequency, clinical and angiographic characteristics, and outcomes of
high-risk non-ST-segment elevation acute coronary syndromes patients
with left circumflex culprit lesions. Halim SA, Clare RM, Newby LK,
Lokhnygina Y, Schweiger MJ, Hof AW, Hochman JS, James SK, White HD,
Widimsky P, Betriu A, Bode C, Giugliano RP, Harrington RA, Zeymer U. Int
J Cardiol. 2015 Nov 10;203:708-713.
Core samples for radiomics features that are insensitive to tumor
segmentation: method and pilot study usin CT images of hepatocellular
carcinoma. Echegaray S, Gevaert O, Shah R, Kamaya A, Louie J, Kothary N, Napel S. J Med Imaging (Bellingham). 2015 Oct;2(4):041011. Epub 2015
Nov 18.
How Can We Further Optimize the Invasive Evaluation of Coro-
nary Physiology? Fearon WF, Tremmel JA. JACC Cardiovasc Interv. 2015
Nov;8(13):1692-4.
Computational modeling of acute myocardial infarction. Sáez P, Kuhl E.
Comput Methods Biomech Biomed Engin. 2015 Nov 19:1-9.
High-throughput sequencing insights into T-cell receptor repertoire di-
versity in aging. Goronzy JJ, Qi Q, Olshen RA, Weyand CM. Genome Med.
2015 Nov 19;7(1):117.
Exercise Strain Echocardiography in Patients With a Hemodynamically
Significant Myocardial Bridge Assessed by Physiological Study. Ko-
bayashi Y, Tremmel JA, Kobayashi Y, Amsallem M, Tanaka S, Yamada R,
Rogers IS, Haddad F, Schnittger I. J Am Heart Assoc. 2015 Nov 18;4(11).
Comparison of left ventricular manual versus automated derived longitu-
dinal strain: implications for clinical practice and research. Kobayashi Y,
Ariyama M, Kobayashi Y, Giraldeau G, Fleischman D, Kozelj M, Vrtovec B,
Ashley E, Kuznetsova T, Schnittger I, Liang D, Haddad F. Int J Cardiovasc
Imaging. 2015 Nov 17.
Paradoxical Vessel Remodeling of the Proximal Segment of the Left An-
terior Descending Artery Predicts Long-Term Mortality After Heart Trans-
plantation. Okada K, Kitahara H, Yang HM, Tanaka S, Kobayashi Y, Kimura
T, Luikart H, Yock PG, Yeung AC, Valantine HA, Fitzgerald PJ, Khush KK,
Honda Y, Fearon WF. JACC Heart Fail. 2015 Oct 31.
Allosteric regulation of G protein-coupled receptor activity by phospho-
lipids. Dawaliby R, Trubbia C, Delporte C, Masureel M, Van Antwerpen P,
Kobilka BK, Govaerts C. Nat Chem Biol. 2015 Nov 16.
c v i . s ta n fo rd .e d u | 20
Lost to Follow-up and Withdrawal of Consent in Contemporary Global Car-
diovascular Randomized Clinical Trials. Rodriguez F, Harrison RW, Wojdyla
D, Mahaffey KW. Crit Pathw Cardiol. 2015 Dec;14(4):150-3.
Cytokines profile in hypertensive patients with left ventricular remodeling
and dysfunction. Kuznetsova T, Haddad F, Knez J, Rosenberg-Hasson Y,
Sung J, Cauwenberghs N, Thijs L, Karakikes I, Maecker H, Mahaffey KW,
Wu JC, Staessen JA. J Am Soc Hypertens. 2015 Oct 17.
The Role of Peer Support in Attaining Ideal Cardiovascular Health: Peer
Pressure and Prevention. Rodriguez F, Harrington RA. J Am Coll Cardiol.
2015 Oct 30.
Identifying and quantifying two ligand-binding sites while imaging native
human membrane receptors by AFM. Pfreundschuh M, Alsteens D, Wieneke
R, Zhang C, Coughlin SR, Tampé R, Kobilka BK, Müller DJ. Nat Commun.
2015 Nov 12;6:8857.
Women in Cardiology: Very Few, Different Work, Different Pay. Hlatky MA,
Shaw L. J Am Coll Cardiol. 2015 Nov 5.
Oxygen regulation of breathing through an olfactory receptor activated by
lactate. Chang AJ, Ortega FE, Riegler J, Madison DV, Krasnow MA. Nature.
2015 Nov 12;527(7577):240-4.
Leukotriene B4 Activates Pulmonary Artery Adventitial Fibroblasts in
Pulmonary Hypertension. Qian J, Tian W, Jiang X, Tamosiuniene R, Sung
YK, Shuffle EM, Tu AB, Valenzuela A, Jiang S, Zamanian RT, Fiorentino
DF, Voelkel NF, Peters-Golden M, Stenmark KR, Chung L, Rabinovitch M,
Nicolls MR. Hypertension. 2015 Dec;66(6):1227-39.
Engineering growth factors for regenerative medicine applications. Mitch-
ell AC, Briquez PS, Hubbell JA, Cochran JR. Acta Biomater. 2015 Nov 7. pii:
S1742-7061(15)30184-7.
Unplanned reoperations after vascular surgery. Kazaure HS, Chandra V,
Mell MW. J Vasc Surg. 2015 Nov 6.
Myocardial Protection During Cardiotoxic Chemotherapy. Witteles RM,
Bosch X. Circulation. 2015 Nov 10;132(19):1835-45.
Novel Noxipoint Therapy versus Conventional Physical Therapy for Chronic
Neck and Shoulder Pain: Multicentre Randomised Controlled Trials. Koo
CC, Lin RS, Wang TG, Tsauo JY, Yang PC, Yen CT, Biswal S. Sci Rep. 2015 Nov
10;5:16342.
Racial Differences in Quality of Anticoagulation Therapy for Atrial Fibrilla-
tion (from the TREAT-AF Study). Yong C, Azarbal F, Abnousi F, Heidenreich PA, Schmitt S, Fan J, Than CT, Ullal AJ, Yang F, Phibbs CS, Frayne SM, Ho
PM, Shore S, Mahaffey KW, Turakhia MP. Am J Cardiol. 2015 Oct 22.
Appropriate Use Criteria for Coronary Revascularization and the Learn-
ing Health System: A Good Start. Harrington RA. JAMA. 2015 Nov
17;314(19):2029-31.
Evidence-Based Management of Stable Ischemic Heart Disease: Challeng-
es and Confusion. Bangalore S, Maron DJ, Hochman JS. JAMA. 2015 Nov
10;314(18):1917-8.
Valve-sparing root replacement for failed pulmonary autografts: Should a
David repair a Ross? Goldstone AB, Woo YJ. J Thorac Cardiovasc Surg. 2015
Nov;150(5):1138-9.
Lift NIH restrictions on chimera research. Sharma A, Sebastiano V, Scott
CT, Magnus D, Koyano-Nakagawa N, Garry DJ, Witte ON, Nakauchi H, Wu JC, Weissman IL, Wu SM. Science. 2015 Nov 6;350(6261):640.
Amiodarone and risk of death in contemporary patients with atrial fibril-
lation: Findings from The Retrospective Evaluation and Assessment of
Therapies in AF study. Ullal AJ, Than CT, Fan J, Schmitt S, Perino AC, Kaiser
DW, Heidenreich PA, Frayne SM, Phibbs CS, Turakhia MP. Am Heart J. 2015
Nov;170(5):1033-1041.e1.
Clinical Relevance of Myocardial Injury After Transcatheter Aortic
Valve Replacement. Fearon WF, Yeung AC. J Am Coll Cardiol. 2015 Nov
10;66(19):2089-91.
Alternative approaches for mitral valve repair. Goldstone AB, Woo YJ. Ann
Cardiothorac Surg. 2015 Sep;4(5):469-73.
Imaging Functional Nucleic Acid Delivery to Skin. Kaspar RL, Hickerson
RP, González-González E, Flores MA, Speaker TP, Rogers FA, Milstone LM,
Contag CH. Methods Mol Biol. 2016;1372:1-24.
Molecular Mechanisms of Right Ventricular Failure. Reddy S, Bernstein D.
Circulation. 2015 Nov 3;132(18):1734-42.
Shear-Thinning Supramolecular Hydrogels with Secondary Autonomous
Covalent Crosslinking to Modulate Viscoelastic Properties In Vivo. Rodell
CB, MacArthur JW, Dorsey SM, Wade RJ, Woo YJ, Burdick JA. Adv Funct
Mater. 2015 Jan 28;25(4):636-644. Epub 2014 Dec 12.
Hyperinsulinemia in individuals with obesity: Role of insulin clearance. Kim
MK, Reaven GM, Chen YI, Kim E, Kim SH. Obesity (Silver Spring). 2015 Nov 2.
Secondary instabilities modulate cortical complexity in the mammalian
brain. Budday S, Steinmann P, Kuhl E. Philos Mag (Abingdon). 2015;95(28-
30):3244-3256. Epub 2015 Mar 30.
Plug The Hole - A Bail-Out Option For Acute Focal Aortic Rupture. Zayed
MA, Marshall C, Dake M, Lee JT. Ann Vasc Surg. 2015 Oct 29.
The contemporary evolution of mitral valve surgery. Woo YJ, Goldstone AB.
J Thorac Cardiovasc Surg. 2015 Oct 9.
DECEMBER 2015: PUBLICATIONS
The Athlome Project Consortium: A Concerted Effort to Discover Genomic
and other “OMIC” Markers of Athletic Performance. Pitsiladis YP, Tanaka M,
Eynon N, Bouchard C, North KN, Williams AG, Collins M, Moran CN, Britton
SL, Fuku N, Ashley EA, Klissouras V, Lucia A, Ahmetov II, de Geus EJ, Al-
sayrafi M. Physiol Genomics. 2015 Dec 29.
Training Pathways in Pediatric Cardiac Intensive Care: Proceedings From
the 10th International Conference of the Pediatric Cardiac Intensive Care
Society. Anand V, Kwiatkowski DM, Ghanayem NS, Axelrod DM, DiNardo
J, Klugman D, Krishnamurthy G, Siehr S, Stromberg D, Yates AR, Roth SJ,
Cooper DS. World J Pediatr Congenit Heart Surg. 2016 Jan;7(1):81-8.
c v i . s ta n fo rd .e d u | 21
Anatomic Factors Associated With Truncal Valve Insufficiency and the Need
for Truncal Valve Repair. Patrick WL, Mainwaring RD, Carrillo SA, Ma M, Re-
inhartz O, Petrossian E, Selamet Tierney ES, Reddy VM, Hanley FL. World J
Pediatr Congenit Heart Surg. 2016 Jan;7(1):9-15.
Theophylline Population Pharmacokinetics and Dosing in Children Follow-
ing Congenital Heart Surgery with Cardiopulmonary Bypass. Frymoyer A, Su
F, Grimm PC, Sutherland SM, Axelrod DM. J Clin Pharmacol. 2015 Dec 29.
Distance from sub-Saharan Africa predicts mutational load in diverse
human genomes. Henn BM, Botigué LR, Peischl S, Dupanloup I, Lipatov M,
Maples BK, Martin AR, Musharoff S, Cann H, Snyder MP, Excoffier L, Kidd
JM, Bustamante CD. Proc Natl Acad Sci U S A. 2015 Dec 28.
Atrial Fibrillation: Can Electrograms Be Interpreted Without Repolarization
Information? Narayan SM, Zaman J, Baykaner T, Franz MR. Heart Rhythm.
2015 Dec 19.
PharmGKB Summary: very important pharmacogene information for RYR1.
Alvarellos ML, Krauss RM, Wilke RA, Altman RB, Klein TE. Pharmacogenet
Genomics. 2015 Dec 24.
Aortic Valve Repair. David TE, Coselli JS, Khoury GE, Miller DC, Svensson
LG. Semin Thorac Cardiovasc Surg. 2015 Autumn;27(3):271-87.
The State of Medical Student Performance Evaluations: Improved Trans-
parency or Continued Obfuscation? Hom J, Richman I, Hall P, Ahuja N,
Harman S, Harrington R, Witteles R. Acad Med. 2015 Dec 22.
Ultrasound-Assisted Liposuction Does Not Compromise the Regenerative Po-
tential of Adipose-Derived Stem Cells. Duscher D, Atashroo D, Maan ZN, Luan
A, Brett EA, Barrera J, Khong SM, Zielins ER, Whittam AJ, Hu MS, Walmsley
GG, Pollhammer MS, Schmidt M, Schilling AF, Machens HG, Huemer GM, Wan
DC, Longaker MT, Gurtner GC. Stem Cells Transl Med. 2015 Dec 23.
The transient receptor potential vanilloid 4 channel modulates uter-
ine tone during pregnancy. Ying L, Becard M, Lyell D, Han X, Shortliffe
L, Husted CI, Alvira CM, Cornfield DN. Sci Transl Med. 2015 Dec
23;7(319):319ra204.
Differences and Trends in DNR among California Inpatients with Heart
Failure. Phadke A, Heidenreich PA. J Card Fail. 2015 Dec 14.
Racial and Ethnic Variations in Lung Cancer Incidence and Mortality: Results
From the Women’s Health Initiative. Patel MI, Wang A, Kapphahn K, Desai M,
Chlebowski RT, Simon MS, Bird CE, Corbie-Smith G, Gomez SL, Adams-Camp-
bell LL, Cote ML, Stefanick ML, Wakelee HA. J Clin Oncol. 2015 Dec 23.
Microfluidics Technologies for Low Cell Number Chromatin Immunoprecip-
itation. Wu AR, Quake SR. Cold Spring Harb Protoc. 2015 Dec 23.
High-degree atrioventricular block, asystole, and electro-mechanical dis-
sociation complicating non-ST-segment elevation myocardial infarction.
Pokorney SD, Radder C, Schulte PJ, Al-Khatib SM, Tricocci P, Van de Werf
F, James SK, Cannon CP, Armstrong PW, White HD, Califf RM, Gibson CM,
Giugliano RP, Wallentin L, Mahaffey KW, Harrington RA, Newby LK, Piccini
JP. Am Heart J. 2016 Jan;171(1):25-32.
Arterial access site and outcomes in patients undergoing percutaneous
coronary intervention with and without vorapaxar. Déry JP, Mahaffey KW,
Tricoci P, White HD, Podder M, Westerhout CM, Moliterno DJ, Harrington RA, Chen E, Strony J, Van de Werf F, Ziada KM, Held C, Aylward PE, Arm-
strong PW, Rao SV. Catheter Cardiovasc Interv. 2015 Dec 23.
Conservative versus invasive stable ischemic heart disease management
strategies: what do we plan to learn from the ISCHEMIA trial? Cheng-Tor-
res KA, Desai KP, Sidhu MS, Maron DJ, Boden WE. Future Cardiol. 2016
Jan;12(1):35-44.
Human induced pluripotent stem cell (hiPSC) derived cardiomyocytes to
understand and test cardiac calcium handling: A glass half full. Hwang HS,
Kryshtal DO, Feaster TK, Sánchez-Freire V, Zhang J, Kamp TJ, Hong CC, Wu JC, Knollmann BC. J Mol Cell Cardiol. 2015 Dec;89(Pt B):379-80.
Molecular pathogenesis and current pathology of pulmonary hyperten-
sion. de Jesus Perez VA. Heart Fail Rev. 2015 Dec 22.
Towards a new era in medicine: therapeutic genome editing. Porteus MH.
Genome Biol. 2015 Dec 22;16(1):286.
Use of protein-engineered fabrics to identify design rules for integrin
ligand clustering in biomaterials. Benitez PL, Mascharak S, Proctor AC,
Heilshorn SC. Integr Biol (Camb). 2015 Dec 21.
Characteristics of Late-Acquired Incomplete Stent Apposition: A Compar-
ison With First-Generation and Second-Generation Drug-Eluting Stents.
Waseda K, Ako J, Kume T, Fitzgerald PJ, Honda Y. J Invasive Cardiol. 2015
Dec 15.
Stem Cell-Based Therapies to Promote Angiogenesis in Ischemic Cardio-
vascular Disease. Hou L, Kim JJ, Woo YJ, Huang NF. Am J Physiol Heart Circ
Physiol. 2015 Dec 18.
Concise Review: Review and Perspective of Cell Dosage and Routes of Ad-
ministration From Preclinical and Clinical Studies of Stem Cell Therapy for
Heart Disease. Golpanian S, Schulman IH, Ebert RF, Heldman AW, DiFede
DL, Yang PC, Wu JC, Bolli R, Perin EC, Moyé L, Simari RD, Wolf A, Hare JM;
Cardiovascular Cell Therapy Research Network. Stem Cells Transl Med. 2015
Dec 18.
Modeling the Lymphatics. Rockson SG. Lymphat Res Biol. 2015
Dec;13(4):233.
Relative dose and vascular response after drug-eluting stent implanta-
tion: A dosimetric 3D-intravascular ultrasound study. Kitahara H, Waseda
K, Yamada R, Sakamoto K, Yock PG, Fitzgerald PJ, Honda Y. Int J Cardiol.
2016 Feb 1;204:211-7.
Time-dependent evolution of functional vs. remodeling signaling in
induced pluripotent stem cell-derived cardiomyocytes and induced
maturation with biomechanical stimulation. Jung G, Fajardo G, Ribeiro AJ,
Kooiker KB, Coronado M, Zhao M, Hu DQ, Reddy S, Kodo K, Sriram K, Insel
PA, Wu JC, Pruitt BL, Bernstein D. FASEB J. 2015 Dec 16.
c v i . s ta n fo rd .e d u | 22
Polypharmacy and the Efficacy and Safety of Rivaroxaban versus Warfarin
in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation.
Piccini JP, Hellkamp AS, Washam JB, Becker RC, Breithardt G, Berkowitz
SD, Halperin JL, Hankey GJ, Hacke W, Mahaffey KW, Nessel CC, Singer DE,
Fox KA, Patel MR. Circulation. 2015 Dec 16.
Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute
Coronary Syndrome Patients Undergoing Noncardiac Surgery. van Diepen
S, Tricoci P, Podder M, Westerhout CM, Aylward PE, Held C, Van de Werf F,
Strony J, Wallentin L, Moliterno DJ, White HD, Mahaffey KW, Harrington RA, Armstrong PW. J Am Heart Assoc. 2015 Dec 15;4(12).
Ablation of Atrial Fibrillation: How Can Less Be More? Zaman JA, Narayan SM. Circ Arrhythm Electrophysiol. 2015 Dec;8(6):1303-5.
Nanoscale Patterning of Extracellular Matrix Alters Endothelial Function
under Shear Stress. Nakayama KH, Surya VN, Gole M, Walker TW, Yang W,
Lai ES, Ostrowski MA, Fuller GG, Dunn AR, Huang NF. Nano Lett. 2015 Dec 28.
Relationship between insulin sensitivity and insulin secretion rate: not
necessarily hyperbolic. Kim SH, Silvers A, Viren J, Reaven GM. Diabet Med.
2015 Dec 16.
The impact of left ventricular ejection fraction on fractional flow reserve:
Insights from the FAME (Fractional flow reserve versus Angiography for
Multivessel Evaluation) trial. Kobayashi Y, Tonino PA, De Bruyne B, Yang
HM, Lim HS, Pijls NH, Fearon WF; FAME Study Investigators. Int J Cardiol.
2016 Feb 1;204:206-10.
A Double-Blinded, Randomized, Placebo-Controlled Clinical Trial of Ami-
nophylline to Prevent Acute Kidney Injury in Children Following Congenital
Heart Surgery With Cardiopulmonary Bypass. Axelrod DM, Sutherland SM,
Anglemyer A, Grimm PC, Roth SJ. Pediatr Crit Care Med. 2015 Dec 11.
Cell-Assisted Lipotransfer Improves Volume Retention in Irradiated Recip-
ient Sites and Rescues Radiation-Induced Skin Changes. Luan A, Duscher
D, Whittam AJ, Paik KJ, Zielins ER, Brett EA, Atashroo DA, Hu MS, Lee GK,
Gurtner GC, Longaker MT, Wan DC. Stem Cells. 2015 Dec 13.
Pearls and pitfalls in managing right heart failure in cardiac surgery. Hadd-ad F, Elmi-Sarabi M, Fadel E, Mercier O, Denault AY. Curr Opin Anaesthesiol.
2016 Feb;29(1):68-79.
Association of Arterial Pulse Pressure With Long-Term Clinical Outcomes
in Patients With Heart Failure. Laskey WK, Wu J, Schulte PJ, Hernandez AF,
Yancy CW, Heidenreich PA, Bhatt DL, Fonarow GC. JACC Heart Fail. 2015 Nov
25.
Computed Tomography Angiography of the Upper Extremities. Dave RB,
Fleischmann D. Radiol Clin North Am. 2016 Jan;54(1):101-14.
Computed Tomography Angiography: A Review and Technical Update.
Fleischmann D, Chin AS, Molvin L, Wang J, Hallett R. Radiol Clin North Am.
2016 Jan;54(1):1-12.
Impact of ventricular assist device placement on longitudinal renal func-
tion in children with end-stage heart failure. May LJ, Montez-Rath ME, Yeh
J, Axelrod DM, Chen S, Maeda K, Almond CS, Rosenthal DN, Hollander SA,
Sutherland SM. J Heart Lung Transplant. 2015 Nov 11.
Systems Genomics Identifies a Key Role for Hypocretin/Orexin Receptor-2
in Human Heart Failure. Perez MV, Pavlovic A, Shang C, Wheeler MT,
Miller CL, Liu J, Dewey FE, Pan S, Thanaporn PK, Absher D, Brandimarto
J, Salisbury H, Chan K, Mukherjee R, Konadhode RP, Myers RM, Sedehi D,
Scammell TE, Quertermous T, Cappola T, Ashley EA. J Am Coll Cardiol. 2015
Dec 8;66(22):2522-33.
Diagnosing Neonatal Aortic Coarctation in the Setting of Patent Ductus
Arteriosus. Peng DM, Punn R, Maeda K, Selamet Tierney ES. Ann Thorac
Surg. 2015 Dec 1.
Stroke Risk Stratification in Atrial Fibrillation: Bridging the Evidence Gaps.
Turakhia MP, Estes NA 3rd. J Cardiovasc Electrophysiol. 2015 Dec 8.
High-throughput analysis and protein engineering using microcapillary
arrays. Chen B, Lim S, Kannan A, Alford SC, Sunden F, Herschlag D, Dimov
IK, Baer TM, Cochran JR. Nat Chem Biol. 2015 Dec 7.
Tau-ism: The Yin and Yang of Microtubule Sliding, Detachment, and Rup-
ture. van den Bedem H, Kuhl E. Biophys J. 2015 Dec 1;109(11):2215-7.
Genetic and Epigenetic Regulation of Human Cardiac Reprogramming and
Differentiation in Regenerative Medicine. Burridge PW, Sharma A, Wu JC.
Annu Rev Genet. 2015 Nov 23;49:461-84.
Generic versus brand-name drugs used in cardiovascular diseases. Manzoli
L, Flacco ME, Boccia S, D’Andrea E, Panic N, Marzuillo C, Siliquini R, Ricciar-
di W, Villari P, Ioannidis JP. Eur J Epidemiol. 2015 Nov 30.
Medical Therapy With Versus Without Revascularization in Stable Pa-
tients With Moderate and Severe Ischemia: The Case for Community
Equipoise. Stone GW, Hochman JS, Williams DO, Boden WE, Ferguson TB
Jr, Harrington RA, Maron DJ. J Am Coll Cardiol. 2015 Nov 2.2015: Selected
Publications
c v i . s ta n fo rd .e d u | 23
Joseph C. Wu, MD, PhDSimon H. Stertzer, MD, Professor & Director, Stanford Cardiovascular Institute, Stanford University School of Medicine
Robert A. Harrington, MDArthur L. Bloomfield Professor of Medicine Chair, Dept. of Medicine
Stephen J. Roth MD, MPHProfessor and Chief, Pediatric CardiologyDirector, Children’s Heart Center
Ronald L. Dalman, MDWalter C. and Elsa R. Chidester Professor of SurgeryChief, Division of Vascular Surgery
Michael Snyder, PhDProfessor and Chair, Dept. of GeneticsDirector, Stanford Center for Genomics and Personalized Medicine
Dominik Fleischmann, MDProfessor, Dept. of RadiologyChief, Cardiovascular Imaging
Y. Joseph Woo, MDNorman E. Shumway Professor in Cardiothoracic SurgeryChair Dept. of Cardiothoracic Surgery
Kenneth Mahaffey, MDProfessor, Dept. of MedicineVice Chair of Medicine for Clinical Research
Alan Yeung, MDLi Ka Shing Professor of MedicineCo-Chief (Clinical), Division of Cardiovascular Medicine
Mark Nicolls, MDAssociate Professor, Dept. of MedicineChief, Pulmonary and Critical Care Medicine
Paul Yock, MDMartha Meier Weiland Professor of Bioengineering and Medicine; and Professor, by courtesy, of Mechanical EngineeringDirector of Biodesign
Tom Quertermous, MDWilliam G. Irwin Professor of MedicineCo-Chief (Research), Division of Cardiovascular Medicine
Marlene Rabinovitch, MDDwight and Vera Dunlevie Professor in Pediatric Cardiology
Leadership